Table 4.
Examples of melanoma treatments undergoing clinical trials.
| Clinical Trial Phase | Clinical Trial Description | Melanoma Stage | Sponsor | Estimated Starting or Completion Date | Trial ID |
|---|---|---|---|---|---|
| 1 | Safety and efficacy of the combination of ipilimumab and imatinib mesylate. | IV | M.D. Anderson Cancer Center | 2013–2024 | NCT01738139 |
| Safety of the combination of panobinostat (histone deacetylase inhibitor) and ipilimumab. | III/IV | H. Lee Moffitt Cancer Center and Research Institute | 2014–2023 | NCT02032810 | |
| Safety and efficacy of the combination of imiquimod and pembrolizumab. | IIIB-IV | Mayo Clinic | 2017–2023 | NCT03276832 | |
| Efficacy of intermittent dosing in the combination of vemurafenib and cobimetinib in the treatment of advanced BRAF V600 mutant melanoma with elevated levels of LDH. | IIIC-IV | H. Lee Moffitt Cancer Center and Research Institute | 2018–2022 | NCT03543969 | |
| Safety of the administration of neoadjuvant atezolizumab treatment before surgery in non-metastatic resectable melanoma. | I/II | The Methodist Hospital Research Institute | 2020–2025 | NCT04020809 | |
| Safety and efficacy of the combination of PeptiCRAd-1 and pembrolizumab. | Inoperable or metastatic | Valo Therapeutics Oy | 2022–2024 | NCT05492682 | |
| 2 | Efficacy of the combination of T-VEC and pembrolizumab. | III/IV | National Cancer Institute | 2017–2023 | NCT02965716 |
| Safety and effectiveness of the combination of PD-L1 (atezolizumab) and anti-VEGF (bevacizumab) therapies. | III/IV | Elizabeth Buchbinder | 2020–2023 | NCT04356729 | |
| Efficacy of the combination of T-VEC and nivolumab. | IIIB/C/D/IVM1a | The Netherlands Cancer Institute | 2020–2023 | NCT04330430 | |
| Safety and efficacy of the combination of pembrolizumab and infliximab. | III/IV | Massachusetts General Hospital | 2022–2025 | NCT05034536 | |
| Safety and efficacy of the combination of PD-1 antibody tislelizumab and dacarbazine. | III/IV | Henan Cancer Hospital | 2022–2024 | NCT05466474 | |
| 3 | Efficacy of the immunization with natural dendritic cells as adjuvant treatment after complete radical lymph node dissection or sentinel node procedure. | IIIB/C | Radboud University Medical Center | 2016–2024 | NCT02993315 |
| Analysis of the safety, efficacy and pharmacokinetic between the combination of atezolizumab, cobimetinib and vemurafenib or combination of only cobimetinib and vemurafenib in previously untreated BRAF V600 mutant melanoma. | IIIC/IV | Hoffmann-La Roche | 2017–2023 | NCT02908672 | |
| Assessment of fixed-dose combination of relatlimab and nivolumab versus nivolumab monotherapy after complete resection. | III/IV | Bristol-Myers Squibb | 2021–2025 | NCT05002569 | |
| Safety and efficacy of the combination of encorafenib and binimetinib in comparison to placebo in BRAF V600E/K mutant melanoma. | IIB/C | Pierre Fabre Medicament | 2022–2035 | NCT05270044 | |
| 4 | Tolerability and long-term safety of dabrafenib and trametinib, alone or in combination. | Advanced or metastatic | Novartis Pharmaceuticals | 2017–2027 | NCT03340506 |
| Safety of pembrolizumab. | III/IV | Merck Sharp & Dohme LLC | 2019–2026 | NCT03715205 |
Abbreviations: BRAF: serine/threonine protein kinase B-raf; LDH: lactate dehydrogenase; PD-L1: programmed death-ligand 1; PeptiCRAd-1: peptide-coated conditionally replicating adenovirus-1; T-VEC: talimogene laherparepvec; VEGF: vascular endothelial growth factor. Data collected from the ClinicalTrials.gov database [126].